How cancer treatments and medicines, including cannabis, affect people with multiple myeloma.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter prospective observational cohort that follows newly diagnosed multiple myeloma patients and compares those who use cannabis with those who do not. Participants complete regular patient-reported outcome surveys (FACT-MM and ESAS), undergo blood sample collection, and have clinical adverse events tracked by CTCAE v5.0; a separate survey is collected from participating healthcare providers. The design captures longitudinal symptom and quality-of-life trajectories during the first-line treatment period (up to four cycles) and excludes patients who have had second-line therapy or autologous stem cell transplant. Comparative analyses will estimate potential symptomatic benefits and harms associated with cannabis use while accounting for concurrent cancer-directed treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \* Documented informed consent of the participant

  * Age: ≥ 18 years
  * ECOG ≤ 3
  * Ability to read and understand English
  * Patient must be newly diagnosed with a histologically confirmed multiple myeloma
  * Patients may have started first line therapies and received up to four cycles
  * HCP SURVEY: Documented informed consent of the participant
  * HCP SURVEY: Age: ≥ 18 years
  * HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse
  * HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients
  * HCP SURVEY: Able to read and understand English
  * HCP SURVEY: Affiliation with City of Hope

Exclusion Criteria:

* \* Patients may not have completed five cycles of first line therapy or undergone any second line therapy

  * Other active malignancy
  * Patients may not have undergone autologous hematopoietic stem cell transplantation
  * Unable to comply with the study assessments
  * HCP SURVEY: Reports directly to study PI (Dr. Richard Lee)
  * HCP SURVEY: Member of the study team or involved in survey design or analysis
  * HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting
• City of Hope at Irvine Lennar
  Irvine, California, United States Recruiting
• CTCA at Western Regional Medical Center
  Goodyear, Arizona, United States Not yet recruiting
• City of Hope Seacliff
  Huntington Beach, California, United States Not yet recruiting
• City of Hope at Long Beach Elm
  Long Beach, California, United States Not yet recruiting
• City of Hope at Newport Beach Fashion Island
  Newport Beach, California, United States Not yet recruiting

Study contacts

• Principal investigator: Richard T Lee — City of Hope Medical Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma

  This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07851493

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.